Digital Aria Co Ltd - Asset Resilience Ratio

Latest as of December 2025: 11.23%

Digital Aria Co Ltd (115450) has an Asset Resilience Ratio of 11.23% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩25.69 Billion
≈ $17.41 Million USD Cash + Short-term Investments

Total Assets

₩228.66 Billion
≈ $154.96 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Digital Aria Co Ltd's Asset Resilience Ratio has changed over time. Check Digital Aria Co Ltd (115450) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Digital Aria Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Digital Aria Co Ltd stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩25.69 Billion 11.23%
Total Liquid Assets ₩25.69 Billion 11.23%

Asset Resilience Insights

  • Moderate Liquidity: Digital Aria Co Ltd has 11.23% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Digital Aria Co Ltd Industry Peers by Asset Resilience Ratio

Compare Digital Aria Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
ALTEOGEN Inc
KQ:196170
Biotechnology 55.57%
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
Biotechnology 47.01%
Definium Therapeutics, Inc.
NASDAQ:DFTX
Biotechnology 34.94%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Galapagos N.V.
AS:GLPG
Biotechnology 86.45%
Blue Jet Healthcare Limited
NSE:BLUEJET
Biotechnology 13.81%
Inventiva S.A
PA:IVA
Biotechnology 52.73%

Annual Asset Resilience Ratio for Digital Aria Co Ltd (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Digital Aria Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 11.23% ₩25.69 Billion
≈ $17.41 Million
₩228.66 Billion
≈ $154.96 Million
-5.95pp
2024-12-31 17.19% ₩37.77 Billion
≈ $25.60 Million
₩219.79 Billion
≈ $148.95 Million
+1.07pp
2023-12-31 16.11% ₩32.35 Billion
≈ $21.92 Million
₩200.79 Billion
≈ $136.08 Million
-17.97pp
2022-12-31 34.08% ₩63.95 Billion
≈ $43.34 Million
₩187.64 Billion
≈ $127.16 Million
-18.90pp
2021-12-31 52.98% ₩100.51 Billion
≈ $68.11 Million
₩189.71 Billion
≈ $128.56 Million
+29.37pp
2020-12-31 23.61% ₩28.79 Billion
≈ $19.51 Million
₩121.94 Billion
≈ $82.64 Million
-10.90pp
2019-12-31 34.51% ₩48.15 Billion
≈ $32.63 Million
₩139.52 Billion
≈ $94.55 Million
+18.85pp
2018-12-31 15.66% ₩16.85 Billion
≈ $11.42 Million
₩107.66 Billion
≈ $72.96 Million
+6.24pp
2017-12-31 9.42% ₩5.91 Billion
≈ $4.00 Million
₩62.71 Billion
≈ $42.50 Million
+0.55pp
2016-12-31 8.87% ₩4.58 Billion
≈ $3.11 Million
₩51.65 Billion
≈ $35.00 Million
+0.93pp
2015-12-31 7.94% ₩4.00 Billion
≈ $2.71 Million
₩50.35 Billion
≈ $34.12 Million
-4.02pp
2014-12-31 11.96% ₩7.00 Billion
≈ $4.74 Million
₩58.52 Billion
≈ $39.66 Million
+11.37pp
2013-12-31 0.59% ₩216.00 Million
≈ $146.38K
₩36.69 Billion
≈ $24.86 Million
+0.01pp
2012-12-31 0.58% ₩313.70 Million
≈ $212.59K
₩54.32 Billion
≈ $36.81 Million
-6.93pp
2011-12-31 7.51% ₩4.67 Billion
≈ $3.17 Million
₩62.23 Billion
≈ $42.17 Million
--
pp = percentage points

About Digital Aria Co Ltd

KQ:115450 Korea Biotechnology
Market Cap
$98.99 Million
₩146.07 Billion KRW
Market Cap Rank
#19158 Global
#909 in Korea
Share Price
₩1657.00
Change (1 day)
+9.01%
52-Week Range
₩1451.00 - ₩3980.00
All Time High
₩25764.90
About

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrica… Read more